Amgen INC. (AMGN).AMGEN AMGEN Applied Molecular Genetics (original meaning) INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (AMGN) Business Overview Amgen Inc. (Amgen), incorporated in 1980, is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. The company operates in one business segment: human therapeutics, It markets human therapeutic products in the areas of inflammation, nephrology and supportive cancer care. Amgen's principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept), which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. Aranesp and EPOGEN stimulate the production of red blood cells Red blood cells Cells that carry hemoglobin (the molecule that transports oxygen) and help remove wastes from tissues throughout the body. Mentioned in: Bone Marrow Transplantation red blood cells to treat anemia. Neulasta and NEUPOGEN stimulate the production of neutrophils neutrophils (ner·ō·trōˑ·filz), n.pl white blood cells with cytoplasmic granules that consume harmful bacteria, fungi, and other foreign materials. , one type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor tumor necrosis factor n. Abbr. TNF A protein that is produced in the presence of an endotoxin, especially by monocytes and macrophages, is able to attack and destroy tumor cells, and exacerbates chronic inflammatory diseases. (TNF TNF abbr. tumor necrosis factor TNF, n an abbreviation for tumor necrosis f ) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. During the year ended December 31,2005, its principal products represented 98% of total product sales. Income Statement LTM * 2005 ** Revenue (billions) $14.3 $12.4 Operating Income (billions) 5.4 5.0 Net Income (millions) 2.6 3.7 EPS $2.48 $2.93 Summary Headquarters: Thousand Oaks Market Cap: $81.7 billion Dividend Yield: N/A P/E Ratio: 18.62 * Latest Twelve Months Ending 12/2006 ** Fiscal Year Ending 12/2005 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion